| abstract |
The present invention is a disease caused by hyperglycemia, which exhibits a wide range of glycemic absorption inhibitory effects and also has a hypoglycemic action based on the intake of fructose in a general meal, and can exert an excellent hypoglycemic action (e.g., For example, a selective SGLT1 inhibitor (e.g., an SGLT1 inhibitor that does not substantially exhibit GLUT2 and / or GLUT5 inhibitory action), which is suitable as an agent for the prevention or treatment of diabetes mellitus, impaired glucose tolerance, diabetic complications, obesity, is an active ingredient. It is to provide a pharmaceutical composition containing as. |